JP2007506442A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007506442A5 JP2007506442A5 JP2006533538A JP2006533538A JP2007506442A5 JP 2007506442 A5 JP2007506442 A5 JP 2007506442A5 JP 2006533538 A JP2006533538 A JP 2006533538A JP 2006533538 A JP2006533538 A JP 2006533538A JP 2007506442 A5 JP2007506442 A5 JP 2007506442A5
- Authority
- JP
- Japan
- Prior art keywords
- expression
- array
- cancer
- ckap4
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 29
- 230000014509 gene expression Effects 0.000 claims 26
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 102100028629 Cytoskeleton-associated protein 4 Human genes 0.000 claims 10
- 101000766853 Homo sapiens Cytoskeleton-associated protein 4 Proteins 0.000 claims 10
- 108091033319 polynucleotide Proteins 0.000 claims 10
- 102000040430 polynucleotide Human genes 0.000 claims 10
- 239000002157 polynucleotide Substances 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 7
- 229940121647 egfr inhibitor Drugs 0.000 claims 7
- 102100024746 Dihydrofolate reductase Human genes 0.000 claims 6
- 102100037859 G1/S-specific cyclin-D3 Human genes 0.000 claims 6
- 102100033044 Glutathione peroxidase 2 Human genes 0.000 claims 6
- 102100027893 Homeobox protein Nkx-2.1 Human genes 0.000 claims 6
- 101000738559 Homo sapiens G1/S-specific cyclin-D3 Proteins 0.000 claims 6
- 101000871129 Homo sapiens Glutathione peroxidase 2 Proteins 0.000 claims 6
- 108010057966 Thyroid Nuclear Factor 1 Proteins 0.000 claims 6
- 108020001096 dihydrofolate reductase Proteins 0.000 claims 6
- 239000000523 sample Substances 0.000 claims 6
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims 5
- 102000004161 Claudin-4 Human genes 0.000 claims 5
- 108090000601 Claudin-4 Proteins 0.000 claims 5
- 102100022334 Dihydropyrimidine dehydrogenase [NADP(+)] Human genes 0.000 claims 5
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 claims 5
- 102100033183 Epithelial membrane protein 1 Human genes 0.000 claims 5
- 102000004961 Furin Human genes 0.000 claims 5
- 108090001126 Furin Proteins 0.000 claims 5
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims 5
- 101000902632 Homo sapiens Dihydropyrimidine dehydrogenase [NADP(+)] Proteins 0.000 claims 5
- 101000850989 Homo sapiens Epithelial membrane protein 1 Proteins 0.000 claims 5
- 101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 claims 5
- 101001027925 Homo sapiens Metastasis-associated protein MTA1 Proteins 0.000 claims 5
- 101000585703 Homo sapiens Protein L-Myc Proteins 0.000 claims 5
- 101000712958 Homo sapiens Ras association domain-containing protein 1 Proteins 0.000 claims 5
- 101000652736 Homo sapiens Transgelin Proteins 0.000 claims 5
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 5
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 claims 5
- 102100037517 Metastasis-associated protein MTA1 Human genes 0.000 claims 5
- 102100030128 Protein L-Myc Human genes 0.000 claims 5
- 102100033243 Ras association domain-containing protein 1 Human genes 0.000 claims 5
- 101150063267 STAT5B gene Proteins 0.000 claims 5
- 102100024474 Signal transducer and activator of transcription 5B Human genes 0.000 claims 5
- 102100031013 Transgelin Human genes 0.000 claims 5
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 5
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 claims 5
- 238000003752 polymerase chain reaction Methods 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 102100031173 CCN family member 4 Human genes 0.000 claims 4
- 102100035139 Folate receptor alpha Human genes 0.000 claims 4
- 101000777560 Homo sapiens CCN family member 4 Proteins 0.000 claims 4
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 claims 4
- 101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 claims 4
- 101000840582 Homo sapiens Insulin-like growth factor-binding protein 6 Proteins 0.000 claims 4
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims 4
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 4
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 claims 4
- 102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 claims 4
- 102100029180 Insulin-like growth factor-binding protein 6 Human genes 0.000 claims 4
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 4
- 102100034256 Mucin-1 Human genes 0.000 claims 4
- 101150038994 PDGFRA gene Proteins 0.000 claims 4
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 claims 4
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 claims 4
- 102100021206 60S ribosomal protein L19 Human genes 0.000 claims 3
- 102100025403 Epoxide hydrolase 1 Human genes 0.000 claims 3
- 102100029283 Hepatocyte nuclear factor 3-alpha Human genes 0.000 claims 3
- 101001105789 Homo sapiens 60S ribosomal protein L19 Proteins 0.000 claims 3
- 101001077852 Homo sapiens Epoxide hydrolase 1 Proteins 0.000 claims 3
- 101001062353 Homo sapiens Hepatocyte nuclear factor 3-alpha Proteins 0.000 claims 3
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 3
- 101000998027 Homo sapiens Keratin, type I cytoskeletal 17 Proteins 0.000 claims 3
- 101001023271 Homo sapiens Laminin subunit gamma-2 Proteins 0.000 claims 3
- 101001116520 Homo sapiens Myotubularin-related protein 11 Proteins 0.000 claims 3
- 101000933173 Homo sapiens Pro-cathepsin H Proteins 0.000 claims 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 3
- 101000577877 Homo sapiens Stromelysin-3 Proteins 0.000 claims 3
- 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 claims 3
- 101000742596 Homo sapiens Vascular endothelial growth factor C Proteins 0.000 claims 3
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 3
- 102100033511 Keratin, type I cytoskeletal 17 Human genes 0.000 claims 3
- 102100035159 Laminin subunit gamma-2 Human genes 0.000 claims 3
- 102100024963 Myotubularin-related protein 11 Human genes 0.000 claims 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 102000018967 Platelet-Derived Growth Factor beta Receptor Human genes 0.000 claims 3
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims 3
- 102100025974 Pro-cathepsin H Human genes 0.000 claims 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 3
- 102100028847 Stromelysin-3 Human genes 0.000 claims 3
- 102100024026 Transcription factor E2F1 Human genes 0.000 claims 3
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims 3
- 238000001574 biopsy Methods 0.000 claims 3
- 102100033824 A-kinase anchor protein 12 Human genes 0.000 claims 2
- 108091093088 Amplicon Proteins 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 101000779382 Homo sapiens A-kinase anchor protein 12 Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 239000002299 complementary DNA Substances 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 238000010195 expression analysis Methods 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 238000013188 needle biopsy Methods 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 150000003384 small molecules Chemical group 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000011277 treatment modality Methods 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47490803P | 2003-05-30 | 2003-05-30 | |
| PCT/US2004/017215 WO2004111273A2 (en) | 2003-05-30 | 2004-05-28 | Gene expression markers for response to egfr inhibitor drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007506442A JP2007506442A (ja) | 2007-03-22 |
| JP2007506442A5 true JP2007506442A5 (enExample) | 2007-07-05 |
Family
ID=33551513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006533538A Pending JP2007506442A (ja) | 2003-05-30 | 2004-05-28 | Ｅｇｆｒ阻害薬への応答に関する遺伝子発現マーカー |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20050164218A1 (enExample) |
| EP (2) | EP2226396A1 (enExample) |
| JP (1) | JP2007506442A (enExample) |
| AU (2) | AU2004248140A1 (enExample) |
| CA (1) | CA2527321A1 (enExample) |
| WO (1) | WO2004111273A2 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7379765B2 (en) | 2003-07-25 | 2008-05-27 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
| US20050059012A1 (en) * | 2002-07-31 | 2005-03-17 | Daniel Afar | Diagnosis of ZD1839 resistant tumors |
| US20050267689A1 (en) * | 2003-07-07 | 2005-12-01 | Maxim Tsypin | Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications |
| US8017321B2 (en) | 2004-01-23 | 2011-09-13 | The Regents Of The University Of Colorado, A Body Corporate | Gefitinib sensitivity-related gene expression and products and methods related thereto |
| EP2527460B1 (en) | 2004-05-27 | 2014-12-24 | The Regents of The University of Colorado | Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients |
| CA2569520C (en) | 2004-06-04 | 2023-03-14 | Genentech, Inc. | Kras mutations for identifying colorectal tumors responsive to cetuximab or panitumumab |
| ATE477495T1 (de) | 2005-03-16 | 2010-08-15 | Osi Pharm Inc | Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor |
| US8383357B2 (en) | 2005-03-16 | 2013-02-26 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| BRPI0609615A2 (pt) | 2005-04-01 | 2010-04-27 | Amgen Inc. | métodos de predição da eficácia de tratamento de agente de ligação especìfica a egfr em tratamento de cáncer relacionado com egfr num sujeito, de tratamento do mesmo e de determinação da eficácia de tratamento em paciente |
| AU2006235258A1 (en) * | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | Cancer-related genes |
| JP2008535508A (ja) * | 2005-04-14 | 2008-09-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 腫瘍組織における増大したコピー数のｅｇｆｒ遺伝子に基づく抗ｅｇｆｒ抗体療法 |
| JP2008541701A (ja) * | 2005-05-04 | 2008-11-27 | ユニヴァーシティ オブ サウス フロリダ | がんの対象における処置応答の予測 |
| EP1913157B2 (en) * | 2005-06-28 | 2016-10-26 | Genentech, Inc. | Egfr and kras mutations for prediction of patient response to egfr inhibitor treatment |
| JP5055284B2 (ja) | 2005-09-20 | 2012-10-24 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | インシュリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー |
| ATE483972T1 (de) * | 2006-02-16 | 2010-10-15 | Ventana Med Syst Inc | Reagenzien und verfahren für krebsprognose und pathologische einstufung |
| US20070207467A1 (en) * | 2006-03-01 | 2007-09-06 | Ming Xu | Detection of lymph node metastasis from gastric carcinoma |
| JP2007252312A (ja) * | 2006-03-24 | 2007-10-04 | Japan Health Science Foundation | 上皮成長因子受容体−チロシンキナーゼ阻害剤に対する肺ガンの感度測定方法および肺ガン治療剤のスクリーニング方法 |
| US8024282B2 (en) * | 2006-03-31 | 2011-09-20 | Biodesix, Inc. | Method for reliable classification of samples in clinical diagnostics using an improved method of classification |
| US7906342B2 (en) | 2006-03-31 | 2011-03-15 | Biodesix, Inc. | Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples |
| US7858389B2 (en) * | 2006-03-31 | 2010-12-28 | Biodesix, Inc. | Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathway |
| US7867775B2 (en) * | 2006-03-31 | 2011-01-11 | Biodesix, Inc. | Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway |
| US7736905B2 (en) * | 2006-03-31 | 2010-06-15 | Biodesix, Inc. | Method and system for determining whether a drug will be effective on a patient with a disease |
| US7858390B2 (en) * | 2006-03-31 | 2010-12-28 | Biodesix, Inc. | Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway |
| US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| RU2008146868A (ru) | 2006-05-18 | 2010-06-27 | Кэрис МПИ, Инк.445 Норт Фифс Стрит, 3-ий Флор, Феникс, Аризона 85004, США (US) | Система и способ определения персонализированого медицинского вмешательства при болезненном состоянии |
| US20070281305A1 (en) * | 2006-06-05 | 2007-12-06 | Sean Wuxiong Cao | Detection of lymph node metastasis from gastric carcinoma |
| ES2530438T3 (es) * | 2006-09-12 | 2015-03-02 | Genentech Inc | Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de KIT o KDR como marcador genético |
| RS56422B1 (sr) | 2007-03-13 | 2018-01-31 | Amgen Inc | K-ras mutacije i terapija anti-egfr antitelom |
| WO2008127719A1 (en) | 2007-04-13 | 2008-10-23 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to kinase inhibitors |
| WO2009023172A2 (en) * | 2007-08-09 | 2009-02-19 | The Johns Hopkins University | Predictions of responsiveness to egfr inhibitors |
| AU2008286334C1 (en) * | 2007-08-14 | 2013-11-14 | F. Hoffmann-La Roche Ag | EGFR inhibitor treatment marker |
| DK2176430T5 (da) * | 2007-08-14 | 2013-09-08 | Hoffmann La Roche | Indikator-markør til EGFR-inhibitor-behandling |
| CN101778950A (zh) * | 2007-08-14 | 2010-07-14 | 霍夫曼-拉罗奇有限公司 | Egfr抑制剂治疗的预测性标记物 |
| JP2010535520A (ja) * | 2007-08-14 | 2010-11-25 | エフ．ホフマン−ラ ロシュ アーゲー | Ｅｇｆｒ阻害因子治療のための予測マーカー |
| BRPI0814354A2 (pt) * | 2007-08-14 | 2015-01-20 | Hoffmann La Roche | Marcador preditivo para tratamento com inibidor de egfr |
| AU2008286335B2 (en) * | 2007-08-14 | 2011-10-27 | F. Hoffmann-La Roche Ag | Predictive marker for EGFR inhibitor treatment |
| WO2009045361A2 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| AU2008307579A1 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| US8273534B2 (en) * | 2008-05-14 | 2012-09-25 | Genomic Health, Inc. | Predictors of patient response to treatment with EGF receptor inhibitors |
| WO2010015538A2 (en) * | 2008-08-05 | 2010-02-11 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
| WO2010015536A1 (en) * | 2008-08-05 | 2010-02-11 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
| WO2010015535A1 (en) * | 2008-08-05 | 2010-02-11 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
| CN102232117A (zh) * | 2008-10-14 | 2011-11-02 | 卡里斯Mpi公司 | 描绘肿瘤类型生物标志模式和特征集的基因靶和基因表达的蛋白靶 |
| JP2012507290A (ja) | 2008-10-29 | 2012-03-29 | ウィリアム・ボーモント・ホスピタル | バイオマーカーの使用方法 |
| GB2463401B (en) | 2008-11-12 | 2014-01-29 | Caris Life Sciences Luxembourg Holdings S A R L | Characterizing prostate disorders by analysis of microvesicles |
| JPWO2010064702A1 (ja) * | 2008-12-05 | 2012-05-10 | 国立大学法人 東京大学 | 癌の予後を予測するためのバイオマーカー |
| JP2012519170A (ja) * | 2009-02-26 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法 |
| JP2013520681A (ja) * | 2010-02-24 | 2013-06-06 | バイオデシックス・インコーポレイテッド | 質量スペクトル分析を用いた、治療薬投与のための癌患者のセレクション |
| CN103237901B (zh) | 2010-03-01 | 2016-08-03 | 卡里斯生命科学瑞士控股有限责任公司 | 用于治疗诊断的生物标志物 |
| AU2011223643A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| WO2011109584A2 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| EP2556172A4 (en) | 2010-04-06 | 2013-10-30 | Caris Life Sciences Luxembourg Holdings | CIRCULATING BIOMARKERS FOR DISEASES |
| EP2668504A4 (en) | 2011-01-28 | 2015-06-10 | Biodesix Inc | PREDICTED FOR THE SELECTION OF METASTATIC BREAST CANCER PATIENTS FOR HORMONAL COMBINATION THERAPY |
| WO2012116040A1 (en) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
| WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| BR112014004762A2 (pt) | 2011-08-31 | 2018-06-19 | Genentech Inc | métodos de determinação da sensibilidade de crescimento de célula tumoral á inibição por um inibidor de quinase de egfr, de identificação de um paciente com câncer que provavelmente irá se beneficiar do tratamento com um inibidor de efgr, de tratamento de um câncer em um paciente, de seleção de uma terapia para um paciente com câncer e de determinação de superexpressão de gene erbb2 em uma célula |
| SG11201400996SA (en) | 2011-09-30 | 2014-04-28 | Genentech Inc | Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells |
| CA2862739A1 (en) * | 2012-02-22 | 2013-08-29 | Alethia Biotherapeutics Inc. | Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer |
| CN103408662A (zh) * | 2013-08-15 | 2013-11-27 | 浙江农林大学 | 一种抗蟾皮转胶蛋白-2重组蛋白的鼠抗血清的制备方法 |
| US9211314B2 (en) | 2014-04-04 | 2015-12-15 | Biodesix, Inc. | Treatment selection for lung cancer patients using mass spectrum of blood-based sample |
| EP3176268B1 (en) * | 2014-07-29 | 2019-07-17 | Wellmarker Bio Co., Ltd. | Novel biomarker for predicting sensitivity to egfr-targeting agent, and use thereof |
| BR112018008865A8 (pt) | 2015-11-02 | 2019-02-26 | Five Prime Therapeutics Inc | polipeptídeos do domínio extracelular cd80 e seu uso no tratamento do câncer |
| KR102406696B1 (ko) * | 2020-06-19 | 2022-06-08 | (주)신테카바이오 | 약물 민감도 판단을 위한 유전자 검출 방법 및 진단용 조성물 |
| JPWO2022255401A1 (enExample) * | 2021-06-03 | 2022-12-08 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4699877A (en) * | 1982-11-04 | 1987-10-13 | The Regents Of The University Of California | Methods and compositions for detecting human tumors |
| USRE35491E (en) * | 1982-11-04 | 1997-04-08 | The Regents Of The University Of California | Methods and compositions for detecting human tumors |
| US7838216B1 (en) * | 1986-03-05 | 2010-11-23 | The United States Of America, As Represented By The Department Of Health And Human Services | Human gene related to but distinct from EGF receptor gene |
| US5015568A (en) * | 1986-07-09 | 1991-05-14 | The Wistar Institute | Diagnostic methods for detecting lymphomas in humans |
| US5202429A (en) * | 1986-07-09 | 1993-04-13 | The Wistar Institute | DNA molecules having human BCL-2 gene sequences |
| US4968603A (en) * | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| US5831066A (en) * | 1988-12-22 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Regulation of bcl-2 gene expression |
| US5858678A (en) * | 1994-08-02 | 1999-01-12 | St. Louis University | Apoptosis-regulating proteins |
| US5830753A (en) * | 1994-09-30 | 1998-11-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof. |
| US6716575B2 (en) * | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
| AU716330B2 (en) * | 1995-12-18 | 2000-02-24 | Sugen, Inc. | Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders |
| US5670325A (en) * | 1996-08-14 | 1997-09-23 | Exact Laboratories, Inc. | Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample |
| US5741650A (en) * | 1996-01-30 | 1998-04-21 | Exact Laboratories, Inc. | Methods for detecting colon cancer from stool samples |
| US5821082A (en) * | 1996-05-23 | 1998-10-13 | St. Louis University Health Sciences Center | Anti-proliferation domain of a human Bcl-2 and DNA encoding the same |
| US6100029A (en) * | 1996-08-14 | 2000-08-08 | Exact Laboratories, Inc. | Methods for the detection of chromosomal aberrations |
| US5952178A (en) * | 1996-08-14 | 1999-09-14 | Exact Laboratories | Methods for disease diagnosis from stool samples |
| US6143529A (en) * | 1996-08-14 | 2000-11-07 | Exact Laboratories, Inc. | Methods for improving sensitivity and specificity of screening assays |
| US5928870A (en) * | 1997-06-16 | 1999-07-27 | Exact Laboratories, Inc. | Methods for the detection of loss of heterozygosity |
| US6020137A (en) * | 1996-08-14 | 2000-02-01 | Exact Laboratories, Inc. | Methods for the detection of loss of heterozygosity |
| US6203993B1 (en) * | 1996-08-14 | 2001-03-20 | Exact Science Corp. | Methods for the detection of nucleic acids |
| US6146828A (en) * | 1996-08-14 | 2000-11-14 | Exact Laboratories, Inc. | Methods for detecting differences in RNA expression levels and uses therefor |
| US5861278A (en) * | 1996-11-01 | 1999-01-19 | Genetics Institute, Inc. | HNF3δ compositions |
| US6245523B1 (en) * | 1996-11-20 | 2001-06-12 | Yale University | Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| US5830665A (en) * | 1997-03-03 | 1998-11-03 | Exact Laboratories, Inc. | Contiguous genomic sequence scanning |
| US6033893A (en) * | 1997-06-26 | 2000-03-07 | Incyte Pharmaceuticals, Inc. | Human cathepsin |
| US6020135A (en) * | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| EP1084273A1 (en) * | 1998-06-06 | 2001-03-21 | Genostic Pharma Limited | Probes used for genetic profiling |
| US6998233B2 (en) * | 1998-06-26 | 2006-02-14 | Sunesis Pharmaceuticals, Inc. | Methods for ligand discovery |
| US6919178B2 (en) * | 2000-11-21 | 2005-07-19 | Sunesis Pharmaceuticals, Inc. | Extended tethering approach for rapid identification of ligands |
| US6335155B1 (en) * | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| US6696558B2 (en) * | 1998-09-09 | 2004-02-24 | The Burnham Institute | Bag proteins and nucleic acid molecules encoding them |
| US9534254B1 (en) * | 1999-02-02 | 2017-01-03 | Abbott Molecular Inc. | Patient stratification for cancer therapy based on genomic DNA microarray analysis |
| US20020039764A1 (en) * | 1999-03-12 | 2002-04-04 | Rosen Craig A. | Nucleic, acids, proteins, and antibodies |
| US6960439B2 (en) * | 1999-06-28 | 2005-11-01 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
| US6692916B2 (en) * | 1999-06-28 | 2004-02-17 | Source Precision Medicine, Inc. | Systems and methods for characterizing a biological condition or agent using precision gene expression profiles |
| US6710170B2 (en) * | 1999-09-10 | 2004-03-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| US6271002B1 (en) * | 1999-10-04 | 2001-08-07 | Rosetta Inpharmatics, Inc. | RNA amplification method |
| US6750013B2 (en) * | 1999-12-02 | 2004-06-15 | Protein Design Labs, Inc. | Methods for detection and diagnosing of breast cancer |
| US6248535B1 (en) * | 1999-12-20 | 2001-06-19 | University Of Southern California | Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens |
| WO2001051661A2 (en) * | 2000-01-13 | 2001-07-19 | Amsterdam Support Diagnostics B.V. | A universal nucleic acid amplification system for nucleic acids in a sample |
| US6322986B1 (en) * | 2000-01-18 | 2001-11-27 | Albany Medical College | Method for colorectal cancer prognosis and treatment selection |
| WO2001055454A1 (en) * | 2000-01-28 | 2001-08-02 | Althea Technologies, Inc. | Methods for analysis of gene expression |
| WO2001075162A2 (en) * | 2000-03-31 | 2001-10-11 | University Of Louisville Research Foundation, Inc. | Microarrays to screen regulatory genes |
| WO2001094629A2 (en) * | 2000-06-05 | 2001-12-13 | Avalon Pharmaceuticals | Cancer gene determination and therapeutic screening using signature gene sets |
| US6974667B2 (en) * | 2000-06-14 | 2005-12-13 | Gene Logic, Inc. | Gene expression profiles in liver cancer |
| US20030165952A1 (en) * | 2000-07-21 | 2003-09-04 | Sten Linnarsson | Method and an alggorithm for mrna expression analysis |
| US6582919B2 (en) * | 2001-06-11 | 2003-06-24 | Response Genetics, Inc. | Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates |
| US6602670B2 (en) * | 2000-12-01 | 2003-08-05 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
| WO2002068579A2 (en) * | 2001-01-10 | 2002-09-06 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
| WO2002057787A2 (en) * | 2001-01-12 | 2002-07-25 | Yale University | Detection of survivin in the biological fluids of cancer patients |
| US7776518B2 (en) * | 2001-01-12 | 2010-08-17 | Yale University | Detection of survivin in the biological fluids of cancer patients |
| EP1373896A2 (en) * | 2001-03-12 | 2004-01-02 | MonoGen, Inc. | Cell-based detection and differentiation of disease states |
| US20040009489A1 (en) * | 2001-09-28 | 2004-01-15 | Golub Todd R. | Classification of lung carcinomas using gene expression analysis |
| WO2003039443A2 (en) * | 2001-11-05 | 2003-05-15 | Deutsches Krebsforschungszentrum | Novel genetic markers for leukemias |
| KR20040064275A (ko) * | 2001-11-09 | 2004-07-16 | 소스 프리시전 메디슨, 인코포레이티드 | 유전자 발현 프로파일을 이용한 질병의 동정, 모니터링,치료 및 생물학적 상태의 확인 |
| US20030198972A1 (en) * | 2001-12-21 | 2003-10-23 | Erlander Mark G. | Grading of breast cancer |
| WO2004046386A1 (en) * | 2002-11-15 | 2004-06-03 | Genomic Health, Inc. | Gene expression profiling of egfr positive cancer |
-
2004
- 2004-05-28 AU AU2004248140A patent/AU2004248140A1/en not_active Abandoned
- 2004-05-28 WO PCT/US2004/017215 patent/WO2004111273A2/en not_active Ceased
- 2004-05-28 US US10/857,715 patent/US20050164218A1/en not_active Abandoned
- 2004-05-28 EP EP10158352A patent/EP2226396A1/en not_active Withdrawn
- 2004-05-28 CA CA002527321A patent/CA2527321A1/en not_active Abandoned
- 2004-05-28 JP JP2006533538A patent/JP2007506442A/ja active Pending
- 2004-05-28 EP EP04753936A patent/EP1636380A2/en not_active Withdrawn
-
2007
- 2007-12-03 US US11/949,535 patent/US20080318230A1/en not_active Abandoned
-
2009
- 2009-12-11 AU AU2009248449A patent/AU2009248449A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007506442A5 (enExample) | ||
| US8198024B2 (en) | Gene expression markers for colorectal cancer prognosis | |
| ES2821300T3 (es) | Predicción de pronóstico para el melanoma de cáncer | |
| US20120028264A1 (en) | Method for using gene expression to determine prognosis of prostate cancer | |
| JP2014509189A (ja) | 結腸ガン遺伝子発現シグネチャーおよび使用方法 | |
| JP7665659B2 (ja) | 循環腫瘍核酸分子のマルチモーダル分析 | |
| CN103403187A (zh) | 结肠直肠癌复发的预后特征 | |
| CN105431738A (zh) | 胃癌的预后预测模型的建立方法 | |
| KR20180002882A (ko) | 유전자 발현 프로파일 및 유방암에 대한 이의 용도 | |
| WO2016118670A1 (en) | Multigene expression assay for patient stratification in resected colorectal liver metastases | |
| US20150024956A1 (en) | Methods for diagnosis and/or prognosis of gynecological cancer | |
| MX2011006926A (es) | Metodos y medios para categorizar una muestra que comprende celulas de cancer colorrectal. | |
| EP1683862B1 (en) | Microarray for assessing neuroblastoma prognosis and method of assessing neuroblastoma prognosis | |
| Somura et al. | A three-gene predictor for early intrahepatic recurrence of hepatocellular carcinoma after curative hepatectomy | |
| EP4486917A2 (en) | Methylated dna markers and assays thereof for use in detecting colorectal cancer | |
| Shimada et al. | cDNA microarray analysis of esophageal cancer: discoveries and prospects | |
| JP2024519082A (ja) | 肝細胞がんのｄｎａメチル化バイオマーカー | |
| CN113957145A (zh) | m6A相关lncRNA在预测小细胞肺癌预后和化疗反应的应用 | |
| CN110846417A (zh) | 头颈部鳞癌诊治标志物 | |
| HK40092784A (zh) | 循环肿瘤核酸分子的多模态分析 | |
| EP4680743A1 (en) | Methods of developing cancer diagnostic models and uses thereof in developing cancer detection methods | |
| HK1166350A (en) | Gene expression markers for colorectal cancer prognosis | |
| HK1166352A (en) | Gene expression markers for colorectal cancer prognosis | |
| HK1162613A (en) | Gene expression markers for colorectal cancer prognosis |